Nivolumab (anti-PD-1)

製品コード：A2002         Batch: A200210

印刷

Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.

製品説明

CAS No. 946414-94-4
Formulation 100 mM Pro-Ac, 20 mM Arg, pH5.0
Isotype Human IgG4
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99%
Protein concentration 10.597mg/ml
Endotoxin Level ＜1EU/mg

カスタマーフィードバック

数据来源于[Data independently produced by , , Clin Cancer Res, 2019, doi:10.1158/1078-0432]

Apoptosis rates of Jurkat cells co-cultured for 72 h with H1975, A549 cells or H1975 with 10 μg/mL nivolumab were analyzed by Annexin V-FITC/PI assay (Left) and quantified (Right).

数据来源于[Data independently produced by , , Ann Surg Oncol, 2019, 26(1):139-147]

Preliminary immunotherapy drug screening using immune checkpoint inhibitors pembrolizumab and nivolumab in LGA organoids immune-enhanced with cells from a lymph node from the same patient. Mitochondrial metabolism was assessed at (c) 24 h and (d) 96 h after administration of the immunotherapy agents. Statistical significance: **p<0.05 between tumor cell-only and immune-enhanced organoids; p<0.05 between drug treatment and control of the same group.

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy [ Cancer Cell, 2024, S1535-6108(24)00080-1] PubMed: 38518774
Base editing screens define the genetic landscape of cancer drug resistance mechanisms [ Nat Genet, 2024, 10.1038/s41588-024-01948-8] PubMed: 39424923
Human papillomavirus-encoded circular RNA circE7 promotes immune evasion in head and neck squamous cell carcinoma [ Nat Commun, 2024, 15(1):8609] PubMed: 39366979
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer [ J Exp Med, 2024, 221(10)e20240152] PubMed: 39190534
Modeling lung adenocarcinoma metastases using patient-derived organoids [ Cell Rep Med, 2024, 5(10):101777] PubMed: 39413736
Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip [ Cell Rep Med, 2024, S2666-3791(24)00241-6] PubMed: 38703767
Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes [ Cell Rep Med, 2024, 5(2):101416] PubMed: 38350451
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target [ Blood Cancer J, 2024, 14(1):75] PubMed: 38697976
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target [ Blood Cancer J, 2024, 14(1):75] PubMed: 38697976
NKG2A+CD8+ T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma [ J Immunother Cancer, 2024, 12(1)e008368] PubMed: 38262706

人間や獣医の診断であるか治療的な使用のためにでない。